214 studies on Liraglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If Liraglutide or Metformin were found to positively influence the telomere-telomerase system or Par-4 in Type 2 Diabetes patients, it would provide novel insights into their mechanisms beyond glucose control. This co…
This comprehensive review underscores the significant potential of liraglutide as an effective therapeutic option for obesity, even in off-label scenarios, providing crucial insights for clinical practice. By synthesi…
The potential for Liraglutide to address both nicotine dependence and weight management simultaneously is significant, as weight gain is a common barrier to successful smoking cessation. This dual-action approach coul…
This Phase 4 clinical trial provides robust evidence reinforcing that liraglutide, a GLP-1 receptor agonist, is effective in reducing systolic blood pressure in patients with Type 2 diabetes and co-existing hypertensi…
This Phase 1 trial is crucial for understanding the fundamental mechanisms by which liraglutide exerts its metabolic effects in obese individuals, even without specific outcome data in the abstract. By clarifying its …
The key implication of this research is to understand if Liraglutide, a common Type 2 diabetes medication, offers additional benefits for bone health, which is often compromised in diabetic individuals. If Liraglutide…
This study is significant because it provides valuable real-world data on the long-term effectiveness of Xultophy® in a diverse patient population, complementing controlled clinical trial findings. Understanding how a…
This study provides compelling preliminary evidence that semaglutide, a well-known GLP-1 receptor agonist, could be a highly effective and novel treatment for intractable diarrhea, offering a new therapeutic option fo…
The findings from this study, once published, could significantly advance our understanding of GLP-1 agonists beyond weight loss, specifically in treating binge eating disorder. If Liraglutide proves effective, it cou…
This Phase III comparative trial is significant because it directly compares three different GLP-1 RA formulations, potentially providing crucial data to guide treatment selection for obese patients. The findings coul…
PCOS is a complex condition with significant unmet needs, particularly for obese and infertile women who struggle with its multifaceted symptoms. If liraglutide demonstrates superior or even comparable efficacy to met…
If successful, this line of research could reposition GLP-1 agonists as potential neuroprotective agents, expanding their therapeutic utility beyond metabolic disorders. The findings, had they been positive, could hav…
This study provides strong evidence that Liraglutide 3.0mg is an effective and generally well-tolerated treatment option for managing weight regain after Roux-en-Y gastric bypass surgery. This is a crucial finding, as…
Understanding how different antidiabetic medications affect liver enzymes like ALT is crucial for managing patients with Type 2 Diabetes Mellitus (T2DM), especially given the high prevalence of co-occurring non-alcoho…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
This study reinforces the efficacy of liraglutide as an add-on therapy for Type 2 Diabetes, particularly within a Japanese population. The findings suggest that combining liraglutide with insulin can lead to better gl…
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
Identifying predictive biomarkers for Liraglutide response could revolutionize obesity treatment by enabling personalized medicine. If successful, this research could allow clinicians to prescribe Saxenda® more effect…
Understanding how age affects Liraglutide's pharmacokinetics is crucial for optimizing treatment strategies, especially given the increasing prevalence of type 2 diabetes and obesity in the elderly population. If sign…
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
This review significantly advances our understanding of the dermatological profile of GLP-1RAs, providing crucial insights for clinicians prescribing these medications. The identification of both common cutaneous adve…
This research is crucial for identifying cognitive-behavioral markers that predict successful long-term weight loss following bariatric surgery or liraglutide treatment. Understanding these markers could lead to more …
This review suggests a paradigm shift in treating bile acid diarrhea, moving beyond traditional bile acid sequestrants to a more targeted physiological approach. The findings strongly support further investigation int…
The findings from this trial, once fully published, could significantly impact clinical guidelines for managing Type 2 Diabetes in the critical post-hospitalization period. Identifying effective non-insulin options li…
While this specific trial did not yield results, the underlying research questions remain highly relevant for Type 1 Diabetes management. Effectively addressing hypoglycemia-induced oxidative stress, inflammation, and…
This foundational Phase 1 study was critical for advancing liraglutide into subsequent clinical development stages. By establishing a preliminary safety and pharmacokinetic profile in humans, it provided the necessary…
This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative h…
This study provides compelling evidence that Liraglutide offers superior benefits for endothelial function compared to Sitagliptin in patients with Type 2 Diabetes. This enhanced endothelial health could translate int…
Establishing bioequivalence is a critical regulatory step in drug development, especially when a drug's formulation changes between clinical trial phases. This ensures that the safety and efficacy data gathered in ear…
Consistent with the study's primary objective and anticipation, liraglutide demonstrated a significantly greater impact on body weight reduction compared to metformin. Participants receiving liraglutide achieved an av…
Prader-Willi Syndrome patients face profound challenges with hyperphagia and severe obesity, which significantly impact their health and quality of life. Liraglutide, with its established appetite-suppressive and weig…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These …
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
This research highlights brain glucose hypometabolism as a crucial, early indicator of Alzheimer's Disease risk. Understanding this sequence could revolutionize early diagnostic strategies, allowing for interventions …
While this specific study was terminated without reporting results, the underlying research question remains highly relevant. If completed, positive findings could have highlighted Liraglutide's potential beyond weigh…
While this specific study did not yield data, the initial intent highlights a critical area of need: understanding how combination therapies like IDegLira perform in real-world settings for patients whose Type 2 Diabe…
Liraglutide is already a cornerstone in managing Type 2 Diabetes and has demonstrated significant cardiovascular benefits, including a 13% reduction in major adverse cardiovascular events in previous trials. This stud…
Understanding the interaction between Liraglutide and clock genes could provide novel insights into the pathogenesis of Type 2 Diabetes and the broader metabolic effects of GLP-1 receptor agonists. This research is cr…
The abstract outlines the study's primary objective to determine the effectiveness and safety of adding GLP-1 agonist therapy to basal insulin. The investigators hypothesized that this combination would lead to statis…